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resulted from transmission of the V2 human prion strain, 
which is associated with the second most common form of 
sporadic CJD.
Keywords Creutzfeldt–Jakob disease · Prion · Iatrogenic · 
Growth hormone · Disease phenotype · Agent strain
Introduction
Prion diseases are a group of fatal transmissible neurode-
generative disorders that occur naturally in man and a range 
of other species [12]. All are associated with the conversion 
of a normal host cellular protein, the prion protein (PrPC), 
into a misfolded disease-associated form, PrPSc, which 
accumulates in the central nervous system (CNS) [29]. The 
prion hypothesis states that PrPSc is the principal (if not the 
sole) component of the transmissible agents responsible for 
this group of diseases [30]; this hypothesis is supported by 
an increasing body of experimental evidence [9]. However, 
the precise relationship between the conformation of PrPSc 
in different forms of prion disease and the biological prop-
erties of the transmissible agents (strain characteristics) in 
different prion diseases is still unresolved.
Unlike the more common forms of human neurodegen-
erative diseases, human prion diseases occur in sporadic, 
genetic and acquired forms [12]. The acquired human 
prion diseases that have resulted from human-to-human 
transmission include kuru (now considered to be extinct) 
and iatrogenic Creutzfeldt-Jakob disease (iCJD), with 
variant Creutzfeldt–Jakob disease (vCJD) resulting from 
bovine to human transmission of the bovine spongiform 
encephalopathy (BSE) agent. Iatrogenic transmission of 
Creutzfeldt–Jakob disease (CJD) has occurred in many 
countries across the world as a consequence of transmission 
Abstract Creutzfeldt–Jakob disease (CJD) is the proto-
typic human prion disease that occurs most commonly in 
sporadic and genetic forms, but it is also transmissible and 
can be acquired through medical procedures, resulting in 
iatrogenic CJD (iCJD). The largest numbers of iCJD cases 
that have occurred worldwide have resulted from contami-
nated cadaveric pituitary-derived human growth hormone 
(hGH) and its use to treat primary and secondary growth 
hormone deficiency. We report a comprehensive, tissue-
based and molecular genetic analysis of the largest series 
of UK hGH-iCJD cases reported to date, including in vitro 
kinetic molecular modelling of genotypic factors influenc-
ing prion transmission. The results show the interplay of 
prion strain and host genotype in governing the molecu-
lar, pathological and temporal characteristics of the UK 
hGH-iCJD epidemic and provide insights into the adaptive 
mechanisms involved when prions cross genotypic barriers. 
We conclude that all of the available evidence is consist-
ent with the hypothesis that the UK hGH-iCJD epidemic 
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via contaminated neurosurgical instruments, intracerebral 
electroencephalography needles, corneal transplantation, 
human dura mater grafts, inoculation with human pituitary 
hormones and (in the case of vCJD) transfusion of packed 
red blood cells [14]. The vast majority of iCJD cases have 
occurred in human dura mater (hDM) graft recipients and 
in recipients of human growth hormone (hGH) derived 
from cadaveric pituitaries [5]. The incubation periods in the 
worldwide cohort of iCJD cases are markedly variable, with 
the shortest incubation periods occurring in those exposed 
via surgical instruments or electrodes used on the CNS 
(1–2.3 years) and the longest occurring in hDM graft recipi-
ents (1.3–30 years), and human pituitary-derived hGH and 
gonadotrophin recipients (5–42 years) [5]. Estimation of 
incubation periods in human pituitary hormone recipients is 
difficult, since the patients are often treated over a period of 
years; the time period from the mid-point of pituitary hor-
mone treatment to the onset of clinical symptoms of iCJD 
is often used as an estimate for the incubation period [33].
The use of pituitary-derived hGH in the treatment of 
primary and secondary growth hormone deficiency in the 
United Kingdom (UK) began as a clinical trial in 1959 and 
became a centrally administered National Health Service 
activity in 1976 [33]. In 1985, the first cases of iCJD in 
patients treated with pituitary-derived hGH were reported 
in the United States of America (USA) and in the UK [10, 
28]. Consequently, the use of pituitary-derived hGH for the 
treatment of growth hormone deficiency was abandoned in 
the UK, USA and many other countries and biosynthetic 
growth hormone is now used for this purpose. The pres-
ence of prion infectivity in hGH preparations in the USA 
was confirmed by experimental intracerebral inoculation 
of samples of pituitary-derived hGH into primates, which 
resulted in the onset of neurological symptoms in a squir-
rel monkey after an incubation period of over 5.5 years 
[11]. Post-mortem examination of the brain of this ani-
mal confirmed the presence of a subacute spongiform 
encephalopathy.
In the UK, 1849 patients were treated with hGH in the 
national scheme from 1959 until 1985 [33]. Since 1985, 78 
deaths from iatrogenic CJD have occurred in this cohort, 
and it has been identified that one particular prepara-
tion of UK pituitary-derived hGH (the Hartree-modified 
Wilhelmi preparation) had been administered to all hGH 
recipients who had developed iCJD [31, 33]. It has also 
been estimated that the risk of developing iCJD in the UK 
hGH recipient cohort was greatest in those patients who 
received treatment at ages 8-10 years with a peak incuba-
tion period of 20 years [33]. Estimated incubation periods 
in the UK hGH-iCJD patients range from 7 to 40 years 
[31]; these prolonged incubation periods are reminiscent of 
those occurring in kuru, where incubation periods of over 
40 years have been reported [8]. In contrast, only eight 
cases of iCJD in hDM graft recipients (hDM-iCJD) have 
been reported in the UK, with incubation periods ranging 
from 3.8 to 14.8 years [13].
Incubation periods in prion diseases have been studied 
extensively under experimental conditions and appear to 
be significantly influenced by both recipient (host) genetic 
factors and the strain properties of the infectious agent [12]. 
The principal human genetic factor influencing this incu-
bation period is the codon 129 polymorphism in the prion 
protein gene (PRNP) of the recipient. It has long been rec-
ognised that homozygosity at this locus may predispose to 
both iCJD and sporadic CJD (sCJD), but differences in the 
frequency of the three possible genotypes (MM, MV and 
VV) have been reported in hGH-iCJD cohorts in different 
countries; in particular, most cases of hGH-iCJD in France 
have belonged to the MM subgroup, whilst in the UK the 
VV and MV subgroups predominate [4]. These differences 
may also reflect the nature of the strain(s) of CJD (presum-
ably sCJD) that were responsible for the iatrogenic disease 
transmission.
Despite the fact that iCJD in hGH recipients has 
occurred in over 200 patients across the world, there have 
been very few detailed studies of the neuropathology, prion 
protein biochemistry and prion protein seeding activity in 
this form of human prion disease. Most reports describe 
only small numbers of cases that are not necessarily rep-
resentative of the cohort in question, particularly with 
respect to the year of diagnosis in relation to the evolving 
time period since iatrogenic exposure to contaminated hGH 
ceased. We now report a detailed study of the largest cohort 
of hGH-iCJD cases reported to date, with detailed char-
acterisation of PrPSc in the brain, correlation with genetic 
and pathological factors and an exploration of the in vitro 
PrP seeding activity present in different genetic subgroups. 
These cases are compared with a limited number of cases 
of hDM-iCJD in the UK, but also a very much larger group 
of sCJD cases drawn from the UK population over a simi-
lar time period. The detailed examination of these cohorts 
has allowed us a unique opportunity to ask fundamental 
questions about person-to-person transmission of prion dis-
ease and the molecular mechanisms involved.
Materials and methods
Cases, inclusion criteria and tissue specimens
All CJD cases examined were of UK origin and were 
referred to the National CJD Research and Surveillance 
Unit (NCJDRSU) between 1991 and 2015. Diagnoses were 
made according to WHO criteria [35]. Inclusion criteria for 
biochemical investigation of iCJD cases were the availabil-
ity of frozen CNS tissue taken at post-mortem, appropriate 
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consent and ethical approval for retention and research 
use and the availability of basic clinical data. All patients 
referred to the NCJDRSU with a diagnosis of CJD who had 
received hGH therapy or a hDM graft and met these criteria 
were included in the study. The study identification num-
ber and basic patient demographic data for 21 hGH-iCJD 
and three hDM-iCJD cases are detailed in Online Resource 
Table 1. Where available, samples of both frozen grey mat-
ter and the corresponding fixed samples from the cerebral 
cortex (frontal, parietal, temporal and occipital cortex), 
cerebellum, thalamus and spinal cord were examined. Data 
from a larger subset of the UK hGH-iCJD cases, includ-
ing some of those for which frozen tissues were not avail-
able were included in genetic analyses. Data from 1080 
unselected cases of UK sCJD of known PRNP codon 129, 
with deaths between 1990 and 2015 were used for genetic 
comparison with the UK hGH-iCJD cases. A smaller 
group of UK sCJD cases (n = 108) that were referred to 
the NCJDRSU during the period 1990–2011 were used for 
biochemical comparison with the hGH-iCJD group. These 
cases were selected on the basis of consent for research 
use, availability of clinical information and sufficient fro-
zen tissue available (minimal set comprising temporal cor-
tex, occipital cortex, parietal cortex and thalamus) for PrPres 
type classification according to the method of Parchi et al. 
[23]. All CJD tissue samples were provided by request 
from the NCJDRSU Brain and Tissue Bank in Edinburgh, 
UK, which is part of the MRC Edinburgh Brain Bank.
Neuropathological analysis
Formalin fixed, formic acid treated, paraffin embedded tis-
sue samples from the frontal, parietal, occipital and tem-
poral cortices, hippocampus, amygdala, basal ganglia, 
thalamus, brainstem, cerebellum and spinal cord (where 
available) were stained with haematoxylin and eosin (H&E) 
and immunohistochemistry carried out for the prion protein. 
Immunohistochemistry was performed using two monoclo-
nal antibodies recognising the prion protein; 12F10/epitope: 
amino acids 142–160 (Bioquote Ltd, York, UK) and KG9/
epitope: amino acids 140–160 (TSE Resource Centre, Ros-
lin Institute, UK) in combination with the highly sensitive 
Novolink™ Polymer Detection System (Leica Biosystems, 
UK; Product RE7280-K). Briefly, 5 µm paraffin embedded 
tissue sections were autoclaved in distilled water (dH2O) 
at 121 °C for 10 min followed by immersion in 96% for-
mic acid for 5 min. Tissue sections were thoroughly washed 
in water before incubating in proteinase K solution (5 µg/
ml) for 5 min. Sections were washed in Tris-buffered saline 
(TBS) [50 mM Tris; 150 mM NaCl; pH 7.6] before incu-
bating with the primary antibodies (12F10, 30 ng/ml; KG9, 
40 ng/ml) diluted in antibody diluent (Leica Biosystems, 
UK: Product RE7133-CE) for 1 h at room temperature. 
After 3 × 5 min washes in TBS, immunolabeling was com-
pleted using the Novolink™ Polymer Detection System. 
After a final wash, staining was visualised with 3, 3′-diam-
inobenzidine (DAB).
Tissue sections were analysed independently by two 
experienced assessors (DLR and JWI). The distribution, 
severity and nature of the spongiform change, neuronal 
loss, gliosis and amyloid plaque formation were assessed 
on H&E sections and scored in a semiquantitative manner 
(0-absent, 1-mild, 2-moderate, 3-severe) [23]. The distri-
bution, severity and nature of the abnormal PrP accumula-
tion detected by immunohistochemistry were also recorded 
[12]. This allowed subclassification by histotyping [23, 25] 
to determine whether the range of neuropathological phe-
notypes identified in the iCJD patients corresponded to 
those occurring in the recognised sCJD subtypes, or not.
Western blot analysis and classification of PrPres types
PrPres types present in brain samples from the hGH-iCJD, 
hDM-iCJD and sCJD cases were determined using the 
refined Western blot protocol of Parchi et al. [23]. Briefly, 
100 mg samples of frozen CNS samples were subjected to 
stringent sample preparation (including strong buffering to 
pH6.9 at 37 °C) and digestion with proteinase K (Roche, 
Lewes, UK) using 10U/ml corresponding to ~200 µg/ml 
(depending on the batch) at 37 °C for 1 h prior to West-
ern blot analysis. Immunodetection of PrP was carried out 
using monoclonal antibody 3F4 (Millipore, Watford, UK; 
Catalogue number MAB1564) at a final concentration of 
75 ng/mL for 1 h, or the monoclonal antibody 12B2 (Cen-
tral Veterinary Institute of Wageningen UR, Lelystad, The 
Netherlands) at a final concentration of 200 ng/ml for 1 h. 
This protocol allows a distinction to be made between 
PrPres types based on the migration of the unglycosylated 
(bottom) band of the typical triplet glycoform pattern. 
Three different unglycosylated PrPres fragment mobili-
ties are recognised within the 21–19 kDa range: type 1 in 
which the unglycosylated PrPres has a molecular mass of 
~21 kDa, type 2 in which the unglycosylated PrPres frag-
ment has a molecular mass of ~19 kDa, and an additional 
type with a mobility of ~20 kDa migrating between type 1 
and 2, and therefore referred to as type i (for intermediate). 
PrPres types 1, i and 2 are not mutually exclusive. Certain 
individual samples and cases contain more than one PrPres 
type. This diversity is recognised by classifying such sam-
ples and cases as 1 + 2 or i + 2.
Real‑time quaking induced conversion (RT‑QuIC)
The method used for the RT-QuIC in vitro conversion assay 
was the one used previously [26, 27] with minor modifi-
cations. Full length hamster recombinant PrP (recPrP, 
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aa 23–231; GenBank accession no. K02234) was used 
as a substrate for seeded conversion. The hamster Prnp 
sequence encodes methionine at the position equivalent to 
codon 129 of the human PRNP gene. Brain samples to seed 
the reactions were prepared by homogenizing frozen, pre-
weighed cerebral cortex tissue samples in phosphate buff-
ered saline (PBS) containing 1 mM EDTA, 150 mM NaCl, 
0.5% Triton X-100 and Complete™ Mini EDTA-free Pro-
tease Inhibitor Cocktail (Roche). The tissue was disrupted 
using one cycle of lysis (45 s, 6 ms−1) in a FastPrep-24 
homogeniser (MP Biomedicals, Santa Ana, CA, USA). An 
appropriate volume of homogenization buffer was used 
to give a final tissue concentration of 10% (w/v). Cellular 
debris was cleared from the homogenates by centrifugation 
at 5200 g at 4 °C for 5 m. Further serial tenfold dilutions of 
the cleared tissue homogenate were made using PBS. The 
100 ml RT-QuIC reactions were set up in quadruplicate 
in the wells of a clear-bottomed black 96-well microplate 
(Fisher Scientific, Loughborough, UK). Stock solutions 
containing the reaction components were filtered through a 
0.22 μM Millex PES filter prior to making a master mix. 
recPrP was the final addition to the master mix, which was 
mixed by gently inverting the tube and then dispensed into 
the wells in 98 μl volumes. At least four replicate analy-
ses were performed on each patient sample. The RT-QuIC 
reactions (final volume = 100 μl, recPrP final concentra-
tion = 0.1 mg/ml) were initiated by the addition of 2 μl of 
a 103-fold dilution of the 10% (w/v) homogenate, which is 
equivalent to 2 × 10−7 g brain (wet mass) per 100 μl reac-
tion. After adding this volume of diluted brain homogenate, 
the final reactions contained PBS, 324 mM NaCl (includ-
ing the NaCl present in PBS), 1 mM EDTA, 10 mM ThT, 
1 × 10-7% Triton™ X-100 and 0.1 mg/ml recPrP. The 
plates were sealed with film, incubated at 42 °C and shaken 
intermittently (87 s shaking at 900 rpm in a double orbital 
configuration followed by a 33 s rest) using a FLUOstar 
OMEGA microplate reader (BMG Labtech). Fluorescence 
readings were taken at 480 nm every 15 min from the bot-
tom of the wells after excitation with 20 flashes per well 
at 450 nm. To quantify prion seeding efficiency we used a 
method based on the one described by Shi et al. [32]. In 
this method, the lag time to conversion is used as an inverse 
measure of seeding potential. The lag period to the start 
of conversion was taken to be the time (in hours) from the 
start of the assay to when the RT-QuIC fluorescence read-
ing was three times the average reading at 0.5 h (the base-
line). A mean lag period for four replicate analyses was 
thus obtained for each patient.
Protein misfolding cyclic amplification
Normal brain homogenates, from humanised transgenic 
mice of the PRNP codon 129 methionine homozygous 
(129MM) and valine homozygous (129VV) genotypes, 
were prepared using a manual homogenizer and conver-
sion buffer (Phosphate-Buffered Saline 1X, 150 mM 
NaCl, 1% Triton X-100 and 1X protease inhibitors) 
to obtain a final 10% weight/volume solution (termed 
the PMCA “substrate”). The homogenized tissue was 
cleared by centrifugation at 2000 rpm for 40 s in a refrig-
erated centrifuge (4 °C), and the supernatant was ali-
quoted and stored at −80 °C. The CJD brain homogen-
ates (termed PMCA “seeds”) were prepared following 
the same method used for substrate preparation. PMCA 
experiments were carried out as described previously 
[1]. Briefly, aliquots of 10% brain homogenate substrate 
were mixed with 10% CJD brain homogenates seeds in 
PCR tubes. Low molecular weight heparin was included 
at 100 μg/ml for all PMCA reactions. Prior to the ampli-
fication procedure, 19 μL of the PMCA reaction mixture 
were taken (from the final volume of 120 μl) for each 
reaction (referred to as the “frozen” sample) for com-
parison with the sonicated samples (referred to as the 
“sonicated” sample). Amplification employed cycles of 
sonication and incubation in a programmable sonicator 
(Qsonica, model Q-700) at 37 °C. A total of 96 PMCA 
cycles were performed comprising 20 s of sonication (at 
an amplitude of 38%, wattage: 278–299) followed by 
29 min 40 s of incubation for each cycle. Frozen and soni-
cated samples were digested with proteinase K, and ana-
lysed by Western blotting using the monoclonal antibody 
3F4 as described previously [1]. Amplification efficiency 
was expressed as the increase in PrPres signal in the soni-
cated compared to the frozen sample, as judged by den-
sitometry of Western blot images acquired and analysed 
using the ChemiDoc™ XRS + System with Image Lab 
Software (Bio-Rad, Hemel Hempstead, UK).
Statistics
In the statistical analysis of the clinical patient information 
statistical significance was determined between the differ-
ent PRNP codon 129 genotypes using a one-way ANOVA 
test followed by the Tukey’s multiple comparisons test. 
Statistical analysis of all clinical data was performed using 
GraphPad Prism software 7.00. In the statistical analysis of 
RT-QuIC data, a two sided Mann–Whitney test was used to 
assess the statistical significance of differences between the 
median RT-QuIC lag periods of sCJD versus hGH-iCJD or 
hDM-iCJD cases. The Kruskal–Wallis test was used for the 
combined analysis of sCJD (VV2, MV2, MM1) and hGH-
iCJD (VV2, MV2) subgroups. These non-parametric tests 
were employed on the basis that the shapes of the distribu-
tions of the lag periods were similar for various subgroups. 
Statistical analysis and graphing of the data was performed 
using GraphPad Prism 7.00.
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Results
PRNP codon 129 genotype of the hGH‑iCJD cases
There have been 78 cases of hGH-iCJD identified in the 
UK from 1985 to the present day. 43 of these had fixed and/
or frozen tissue referred for diagnosis at the NCJDRSU. 
Of these 43 cases, 40 were autopsy cases and three were 
biopsy cases. 37 of these 43 cases had available codon 129 
genotype data. 21 of the autopsy cases had frozen CNS tis-
sues that were available for research use. The study iden-
tification numbers with clinical and pathological features 
of these 21 autopsy cases are shown in Online Resource 
Tables 1 and 2, respectively. When the hGH-iCJD patient 
PRNP codon 129 status is considered by year of death the 
following becomes apparent: first, the 21 cases of hGH-
iCJD with frozen tissue analysed in this study died dur-
ing the period from 1990 to 2012, and consequently these 
cases provide examples from the leading edge, the peak 
and the tail of the epidemic (Fig. 1a, b). Second, the UK 
hGH-iCJD group is dominated by patients of the MV and 
VV PRNP codon 129 genotypes; the few hGH-iCJD cases 
that occurred in individuals with an MM PRNP codon 129 
genotype tended to occur later than those of the MV and 
VV PRNP codon 129 genotypes (Fig. 1a, b). In contrast, 
the MM PRNP codon 129 genotype is the most frequently 
occurring group within the UK sCJD group overall, and 
in every year during the hGH-iCJD epidemic (Fig. 1c). 
Finally, when considered as a whole, the distribution of 
codon 129 genotypes of the 21 available hGH-iCJD cases 
and the 108 sCJD cases selected for study here differ from 
each other and from the normal UK population, but they 
appear to be broadly representative subsets of the larger 
hGH-iCJD and sCJD cohorts (Fig. 1d). The three hDM-
iCJD cases were all of the PRNP codon 129 MM genotype 
(Online Resource Table 2).
hGH‑iCJD patient information in relation to PRNP 
codon 129 genotype group
Age at death, duration of hGH treatment and estimated 
incubation periods were similar between the PRNP codon 
129 MV and VV genotype hGH-iCJD groups, but the 
incubation periods in the two MM cases were longer. In 
Fig. 1  PRNP codon 129 genotype of hGH-iCJD and sCJD patient 
groups. a Shows the PRNP codon 129 distribution of hGH-iCJD 
cases by year of death for the 21 cases investigated in this study. b 
Shows the PRNP codon 129 distribution of hGH-iCJD cases by year 
of death for the 37 cases for which PRNP codon 129 data is avail-
able to us. c Shows the PRNP codon 129 distribution by year of death 
for the 1080 UK sCJD cases from 1990 to 2015. d Compares the 
PRNP codon 129 distribution of the hGH-iCJD (n = 21) and sCJD 
(n = 108) cases with frozen tissue analysed in this study, with the 
cases shown in b and c, of which they are a subset. The UK nor-
mal population PRNP codon 129 genotype distribution (UK pop), is 
shown for reference
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contrast, the mean disease duration of illness of the MV 
group was longer than that of both the VV and MM groups 
(Online Resource Table 3).
PrPres types found in the hGH‑iCJD cases
Western blot analysis of all available CNS tissue from the 
21 cases of hGH-iCJD for protease resistant prion pro-
tein (PrPres) was performed. Four PrPres types were iden-
tified in the hGH-iCJD cases, differing in the mobility 
and in the number of unglycosylated bands found. Repre-
sentative examples of the PrPres types 1, i, i + 2 and 2 in 
these cases are shown in Fig. 2a, example Western blots 
for each individual case are shown in Fig. 3, and the data 
compiled with the PRNP codon 129 genotype are shown 
in Online Resource Tables 1 and 2. The majority of cases 
were characterised by the presence of the 19 kDa type 2 
PrPres band (19/21 cases). However, in 12 out of these 19 
cases the 20 kDa type i PrPres band was also present. The 
relative abundance of the 19 kDa type 2 PrPres band and 
the 20 kDa type i PrPres band was variable, but the 19 kDa 
type 2 PrPres band usually predominated (Fig. 3a). Type i 
was found to predominate overall in only one hGH-iCJD 
case (hGH-iCJD20) and the 21 kDa type 1 PrPres was 
found in only one hGH-iCJD case (hGH-iCJD21). In con-
trast to the hGH-iCJD cases, all three cases of hDM-iCJD 
cases had type 1 PrPres exclusively (Fig. 3b). Where it 
could be assessed, regional variation within the brain was 
largely confined to the presence or absence of the PrPres 
type i band and the relative abundance of PrPres types i 
and 2 bands (Online Resource Table 4). Comparison of the 
immunoreactivity of the 21 kDa type 1, 20 kDa type i, and 
19 kDa type 2 bands using the 3F4 antibody (epitope 106-
112) with the 12B2 antibody (epitope 89-93) showed that 
the 21 kDa type 1 PrPres and the 20 kDa type i PrPres frag-
ments both retain the 12B2 epitope, whereas type 2 PrPres 
Fig. 2  PrPres type found in 
the iCJD cases examined. a 
Four PrPres molecular types 
were detected by Western blot 
analysis of proteinase K treated 
brain extracts of hGH-iCJD 
patients; type 1, type i, type 
i + 2 and type 2. Representa-
tive blots of each PrPres type are 
shown. Each sample (middle 
lane) is flanked by type 1 (T1) 
(left lane) and type 2 (T2) (right 
lane) reference standards from 
sCJD MM1 and VV2 sub-
type cases, respectively. Case 
number and codon 129 PRNP 
genotype are indicated above 
each blot, whilst PrPres type 
is indicated below. The most 
informative exposure for the test 
and reference standard samples 
from a series of timed exposures 
is shown. Blots were probed 
using the monoclonal antibody 
3F4. b Western blot analysis of 
proteinase K treated samples of 
PrPres types detected in hGH-
iCJD patients using the mono-
clonal antibody 12B2 which 
detects type 1 PrPres and shown 
after a prolonged (30 min) and 
abbreviated (3 min) exposure 
time. Approximate molecu-
lar mass is shown in kDa. 
The immunoblots shown are 
representative of at least three 
technical repeats
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fragments do not (Fig. 2a, b). Analysis of the PrPres types 
found in the CNS of 108 sCJD cases showed type 1, type 
2, type i + 2 and cases in which type 1 and type 2 were 
found in individual brains, either in the same or in differ-
ent regions (Online Resource Table 5). These latter cases 
were designated type 1 + 2, irrespective of the relative 
abundance and location of the two types. The breakdown 
of these 108 sCJD cases according to the combination of 
CNS PrPres type and PRNP codon 129 genotype is shown 
in Online Resource Table 6, while the histotypes and PrPres 
types associated with the PRNP codon 129 MV sCJD cases 
are shown in Online Resource Table 7. 
PrPres type and PRNP codon 129 genotype of the 
hGH‑iCJD cases
When the 21 cases of hGH-iCJD were grouped accord-
ing to the combination of PRNP genotype and CNS PrPres 
type (Online Resource Table 2; Fig. 4a) all PRNP codon 
129 VV hGH-iCJD cases (7/7) were found to have type 2 
PrPres exclusively. All of the hGH-iCJD PRNP codon 129 
MV genotype cases were found to have type i + 2 PrPres 
(12/12). Of the two PRNP codon 129 MM genotype cases 
found within the hGH-iCJD cohort, one had type 1 PrPres 
and the other had type i PrPres. In contrast, within the 108 
sCJD cases, those with type 1 PrPres and a PRNP codon 
129 MM genotype predominated (50/108) and cases with 
type 1 + 2 PrPres were relatively common (26/108), but 
no examples of type i PrPres alone were found (Online 
Resource Table 6; Fig. 4b). The three hDM-iCJD cases 
were in individuals of the PRNP codon 129 MM genotype 
and each had PrPres type 1 in the CNS (Fig. 3b).
Neuropathology of hGH‑iCJD
The neuropathological features were reviewed in the 21 
hGH-iCJD patients (fixed tissue from case hGH-iCJD1 
was not available for PrP immunohistochemistry). All 
cases showed a general widespread spongiform encepha-
lopathy of a predominantly microvacuolar type accompa-
nied by neuronal loss and gliosis, with amyloid plaques in 
the cerebellum in 13/21 cases. The patterns of accumula-
tion of the disease-associated prion protein on immunohis-
tochemistry were recorded in the 20 cases with available 
material. A summary of the neuropathological features 
of each hGH-iCJD case is added to the PRNP codon 129 
genotype and PrPres type in Online Resource Table 2 and 
example micrographs are shown in Fig. 5 (the neuropatho-
logical features in this cohort will be described more fully 
in a separate manuscript). Overall, the patterns of pathol-
ogy in the hGH-iCJD patients showed close similarities 
with sCJD patients of the corresponding PRNP codon 129 
genotype.
Immunohistochemistry on tissue sections from PRNP 
codon 129 VV hGH-iCJD patients showed a combination 
of synaptic, perineuronal and plaque-like deposits of PrP 
in the cerebral cortex often in a distinctive linear distribu-
tion in the deeper cortical layers, a pattern of PrP pathology 
very similar to that in the VV2 subtype of sporadic CJD 
(Fig. 5a, i). The cerebellum in these cases showed a coarser 
deposition of PrP with occasional plaque-like deposits 
(Fig. 5e, m). In contrast, all PRNP codon 129 MV hGH-
iCJD patients were characterised by a pathology domi-
nated by the accumulation of large and numerous kuru-type 
amyloid plaques in the cerebellar cortex and frequently in 
the cerebral cortex and basal ganglia, consistent with that 
observed in the sCJD MV2 subtype (Fig. 5b, f, j, n). The 
two hGH-iCJD PRNP codon 129 MM cases available for 
analysis showed strikingly different patterns of neuropa-
thology. In patient hGH-CJD20, the spongiform change 
comprised a mixture of both microvacuolar and confluent 
types, with PrP staining showing a combination of synap-
tic, perineuronal and perivacuolar PrP deposits (Fig. 5c). 
In addition, plaque-like deposits and kuru plaques were 
a prominent feature in the cerebral and cerebellar cortex 
from this case (Fig. 5g). In contrast, hGH-CJD21 showed 
spongiform change of predominantly the microvacuolar 
type with a widespread synaptic/granular pattern of PrP 
deposition, a pattern more consistent with that observed in 
the sCJD MM1 subtype (Fig. 5d, h, k, o). In the two hDM-
iCJD cases in which fixed tissue was available for immuno-
histochemical analysis, both showed a synaptic deposition 
of PrP throughout the brain. Kuru-type amyloid plaques or 
plaque-like PrPres deposits were not observed in either case 
(Fig. 5l, p).
Comparison of the amyloid seeding potential 
of hGH‑iCJD and sCJD
The amyloid seeding activity of hGH-iCJD and sCJD cases 
was compared using the real-time quaking induced conver-
sion assay (RT-QuIC). hGH-iCJD cases were selected on 
the basis of the availability of frozen cerebral cortex samples 
(n = 20). sCJD cases (n = 28) were selected on the basis of 
PrPres type and PRNP codon 129 genotype to match, as far 
as possible, those found in the hGH-iCJD cohort. RT-QuIC 
assays were seeded with CJD cerebral cortex homogenate 
diluted by a factor of 2 × 10−5 (each 100 μl RT-QuIC reac-
tion was seeded with the equivalent of 2 × 10−7 g brain) 
and the seeding activity for each patient was assumed to be 
inversely proportional to the mean lag period (Table 1). The 
hGH-iCJD and sCJD seed amounts were determined empir-
ically to be within the range for quantifying seeding activity 
by the lag time method. The hGH-iCJD group as a whole 
(and their subgroups) have a lower median seeding activity 
than the sCJD group (and their matched subgroups). The 
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difference is significant for the hGH-iCJD group as a whole 
and for the VV and MV subgroups. The two PRNP codon 
129 MM hGH-iCJD cases had noticeably different lag times 
in this assay (hGH-iCJD20 at 43.5 h and hGH-iCJD21 at 
27.5 h). Three hDM-iCJD cases were also analysed by RT-
QuIC and their median lag period (34.2 h) was also greater 
than the sCJD MM1 subgroup, but this difference was not 
statistically significant. Although these experiments were 
conducted with recombinant hamster PrP, and therefore 
with a substrate containing methionine at the position equiv-
alent to human codon 129, our previous experience with 
RT-QuIC indicates that it is less sensitive than PMCA to the 
biologically relevant effects of seed and substrate sequence 
matching or mismatching [26].
Comparison of the in vitro amplification of hGH‑iCJD 
and sCJD
The seeding characteristics of the two divergent hGH-iCJD 
PRNP codon 129 MM cases (hGH-iCJD20 and hGH-
iCJD21) were further examined using protein misfolding 
cyclic amplification (PMCA). Samples of cerebral cortex 
were used to seed matched (PRNP codon 129 MM, desig-
nated HuMM) and mismatched (PRNP codon 129 VV, des-
ignated HuVV) PRNP transgenic mouse brain substrates 
and the results compared with those of sCJD subtypes. 
PMCA reactions seeded with cerebral cortex samples from 
cases of sCJD of the MM1 subtype amplified poorly under 
the conditions used, whether in matched (MM) or mis-
matched (VV) humanised transgenic mouse brain substrate 
(Fig. 6a). This was also true of the three hDM-iCJD cases 
(hDM-iCJD1-3) (Fig. 6a). Seeding of PMCA reactions with 
cerebral cortex samples from cases of sCJD of the VV2 
subtype amplified more efficiently under these same condi-
tions, with the amplification levels higher in the matched 
(HuVV) than in the mismatched (HuMM) humanised trans-
genic mouse brain substrate (Fig. 6a). The two hGH-iCJD 
PRNP codon 129 MM cases gave divergent results: hGH-
iCJD20 amplified well and more efficiently in the HuVV 
substrate, whereas hGH-iCJD21 failed to seed either sub-
strate efficiently (Fig. 6a). This difference in amplification 
efficiency and substrate preference between hGH-iCJD20 
and hGH-iCJD21 was independent of seeding dilution 
(Fig. 6a). In the case of hGH-iCJD20, the choice of PRNP 
codon 129 substrate (HuMM or HuVV) also had an effect 
on the PrPres type of the PMCA product when analysed by 
Western blotting (Fig. 6b). The cerebral cortex sample from 
hGH-iCJD20 was PrPres type i, but matching of the MMi 
seed with the HuMM substrate resulted in an upshift in 
mobility of the reaction product, whereas mismatching the 
MMi seed with the HuVV substrate resulted in an apparent 
downshift in mobility of the reaction product. hGH-iCJD21 
amplified only poorly, and there was no evidence of any 
change in the type 1 PrPres when the PMCA products were 
analysed by Western blotting (Fig. 6b). Addition examples 
of this reproducible, albeit subtle, mobility shift are shown 
(Online Resource Fig. 1). The possibility that PrPres type i 
results from replication of the sCJD with type 2 PrPres in an 
individual with a PRNP codon 129 MM genotype was then 
modelled using PMCA. When sCJD VV2 subtype brain 
homogenate was used to seed the HuMM substrate, an 
upward shift was seen, whereas amplification of the same 
seed in a PRNP codon 129 VV genotype resulted in con-
servation of the type 2 PrPres (Fig. 6c). Further examples of 
this phenomenon using four different cases of sCJD VV2 
subtype are shown (Online Resource Fig. 2).
Comparison of the two hGH‑iCJD PRNP codon 129 
MM cases
PRNP codon 129 MM is the rarest genotype within the UK 
hGH-iCJD cohort and cases with this genotype have tended 
to occur late during the epidemic. The two hGH-iCJD 
PRNP codon 129 MM cases available to this study were 
divergent in their neuropathology, PrPres type and amplifi-
cation potential in both the RT-QuIC and PMCA assays. In 
each of these respects, hGH-iCJD21 resembled the sCJD 
MM1 subtype (and the limited number of hDM-iCJD cases 
analysed), whereas hGH-iCJD20 more closely resembled 
the sCJD MV2 or VV2 subtypes, despite its PRNP codon 
129 MM genotype. These data are summarised in Table 2 
and Fig. 7.
Discussion
This study provides a thorough molecular genetic descrip-
tion of the largest series of UK hGH-iCJD epidemic pub-
lished to date, including as it does a large number of cases 
(21 compared to seven in a recent study [31]) in which the 
pathology, biochemistry and genetics can be compared. It 
also provides a description of the leading edge, peak and 
tail of the epidemic, rather than focussing largely on the 
tail of the epidemic [31]. In doing so, this study provides 
a unique opportunity to investigate the molecular epide-
miology of prion transmission within a species, but across 
PRNP codon 129 polymorphic barriers.
Fig. 3  PrPres type found in each individual iCJD case examined. 
PrPres typing of (a) hGH-iCJD cases 1–21 and (b) hDM-iCJD cases 
1–3. Each sample (middle lane) is flanked by a type 1 (left lane) and 
type 2 (right lane) reference standard from sCJD MM1 and VV2 sub-
type cases, respectively. Study identification number, PRNP codon 
129 genotype and brain region are indicated above each blot and 
PrPres type is indicated below. Approximate molecular mass is shown 
in kDa. The immunoblots shown are representative of at least three 
technical repeats
◂
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The UK hGH-iCJD epidemic is widely thought to result 
from contamination of hGH batches with prions present 
in tissue (either pituitary or brain) collected from one, or 
more cases of “classical” Creutzfeldt-Jakob disease. On the 
balance of probabilities, this is more likely to be a form of 
sCJD (rather than a genetic form) since sCJD accounts for 
~85% of human prion disease cases [12]. Although it can-
not be known with certainty, the thesis proposed here is that 
the epidemiology of the epidemic is consistent with con-
tamination with a single major prion strain.
Prion transmission (susceptibility, incubation period and 
phenotype) can be considered as an interaction between 
agent strain and host genotype, mediated in part by the 
related properties of abnormal prion protein conformation 
(for which PrPres type is a surrogate marker) and the PRNP 
polymorphism that the encodes the residue at position 129 
of the prion protein (either M or V). At present, five sCJD 
prion strains (designated M1, M2(c), M2(t), V1 and V2) 
have been distinguished by transmission studies in PRNP 
humanised transgenic mice and nonhuman primates and 
the V2 strain has been proposed to account for both MV2 
and VV2 sCJD [3, 21, 24]. The surfeit of PRNP codon 129 
MM hGH-iCJD cases in France, compared to the predomi-
nance of PRNP codon 129 VV hGH-iCJD cases in the 
UK as of 2003 was suggested to be attributable to differ-
ent contamination events by different strains of agent [4]. 
Given that the two most frequently occurring subtypes of 
sCJD are the MM1 and VV2 subtype, the simplest hypoth-
esis is that the French hGH-iCJD epidemic was caused 
primarily by contamination with MM1 sCJD (i.e. the M1 
sCJD strain) and the UK hGH-iCJD epidemic caused pri-
marily by VV2 or MV2 sCJD contamination (i.e. the V2 
sCJD strain).
The data presented here and those of Rudge et al. 
[31] are consistent with that explanation, coupled with 
the PRNP genotype frequency of the at-risk hGH treated 
patient group, which if similar to UK control (e.g. blood 
donor) groups would be 44% MM, 45% MV and 11% VV 
[2]. Hence, the early surfeit of PRNP codon 129 VV UK 
hGH-iCJD cases could reflect the absence of a genotypic 
barrier and shorter incubation periods, albeit in a small 
subset of the hGH treated patient group. The appearance 
of more numerous cases in PRNP codon 129 MV indi-
viduals may reflect the larger numbers of PRNP codon 
129 MV individuals in the hGH treated patient group. The 
appearance of a limited number of PRNP codon 129 MM 
hGH-iCJD cases, comparatively late in the epidemic, even 
although the hGH treated patient group would be expected 
to be ~40%, could be interpreted as evidence of a substan-
tial PRNP codon 129 genotypic barrier to transmission of 
sCJD of the VV2 or MV2 subtypes, or a very prolonged 
incubation period. Although we cannot completely dis-
count a mixture of contaminating strains including M1 in 
the form of sCJD MM1/MV1 subtype, the late appearance 
of these MM cases argues against a second minor M1 con-
taminating strain.
Our comprehensive data set coupled with the use of 
in vitro molecular conversion systems can be used to refine 
that model and provides a possible molecular mecha-
nism for cross-genotype transmission. Within sCJD cases 
with PRNP codon 129 MV and PrPres type 2, some cases 
have kuru plaques (the MV2K subtype), whereas others 
do not (the MV2C subtype). The MV2K sCJD subtype is 
characterised by PrPres type i + 2 (a doublet of approxi-
mately 20 kDa and 19 kDa), whereas the MV2C subtype is 
reported to be characterised by the 19 kDa band only, and 
Fig. 4  PrPres type and PRNP codon 129 genotype of the hGH-iCJD 
and sCJD groups. a Shows the numbers of cases found within the 
hGH-iCJD group (n = 21) according to the combination of PrPres 
type (inner ring) and PRNP codon 129 genotype (outer ring). b 
Shows the numbers of cases found within the sCJD group (n = 108) 
according to the combination of PrPres type (inner ring) and PRNP 
codon 129 genotype (outer ring)
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termed type 2 [17, 23, 24]. We note that all PRNP codon 
129 MV UK hGH-iCJD cases had PrPres type i + 2 (12/12) 
and kuru plaques. One of the two PRNP codon 129 MM 
hGH-iCJD cases described (hGH-iCJD20) also had kuru 
plaques (not normally found in PRNP codon 129 MM 
sCJD cases) and an intermediate ~20 kDa PrPres type (type 
i), perhaps suggestive of a causal link to the MV2K sub-
type of sCJD. Moreover, the in vitro amplification char-
acteristics of PrPres from this case when used to seed the 
cell free prion protein conversion assay PMCA were not 
Fig. 5  Characteristic neuropathology of the sCJD and iCJD cases. 
Prominent patterns of PrP pathology in the cerebral and cerebel-
lar cortex in UK hGH-iCJD (a–h), sCJD (i–k, m–o) and hDM-iCJD 
patients (l, p). PRNP codon 129 VV hGH-iCJD patients showed a 
combination of synaptic, perineuronal and plaque-like deposits of PrP 
in the cerebral and cerebellar cortex (a, e). Intensely labelled kuru 
plaques and smaller plaque-like deposits were prominent features of 
the cerebral and cerebellar cortex in PRNP codon 129 MV hGH-iCJD 
patients (b, f). Contrasting patterns of PrP pathology were observed 
in the two PRNP codon 129 MM hGH-iCJD patients. Patient hGH-
iCJD20 showed plaque-like deposits in the cerebral cortex (c) and 
numerous kuru plaques in the cerebellum (g) whereas hGH-iCJD21 
showed only synaptic PrP deposits (d, h). The VV2 subtype in sCJD 
shows a perineuronal and synaptic pattern of PrP deposits in the cer-
ebral and cerebellar cortex (i, m). The MV2 subtype of sCJD shows a 
synaptic and perineuronal deposition of PrP in the cerebral cortex (j) 
with kuru plaques and plaque-like deposits of PrP a dominant feature 
in the cerebellum (n). A widespread synaptic pattern of PrP accumu-
lation is the characteristic feature of the MM1 subtype of sCJD (k, 
o). The two UK hDM-iCJD patients were also characterised by a pre-
dominantly synaptic pattern of PrP accumulation in the cerebral and 
cerebellar cortex (l, p). The anti-PrP antibody KG9 was used. Scale 
bars 50 µm
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consistent with its PRNP codon 129 MM genotype, instead 
showing a preference for a substrate containing PrPC with 
valine rather than methionine at position 129. This situation 
is highly reminiscent of the molecular trace-back phenom-
enon proposed by Kitamoto and coworkers to explain the 
phenotypic diversity of the MV2 sCJD cases, and the trans-
mission properties and origin of dura mater-associated CJD 
in Japan [15, 16, 18]. Furthermore, Kobayashi et al. [19, 
20] have proposed that kuru plaques in PRNP codon 129 
MM apparent sCJD cases can be used as an indication of 
an iatrogenic rather than idiopathic/sporadic aetiology. The 
characterisation of our case hGH-iCJD20 here extends the 
trace-back phenomenon of Kitamoto and coworkers from 
dura mater-associated transmissions in Japan to UK growth 
hormone associated transmissions. One of our PRNP codon 
129 MM hGH-iCJD cases has some similarities to one case 
recently described in a group of three hGH-iCJD cases in 
the USA [6]. The association of a PRNP codon 129 MM 
genotype with kuru plaques in three national independent 
iCJD cohorts adds weight to the trace-back hypothesis. 
Moreover, our data using PMCA also confirms that evi-
dence of the trace-back phenomenon in hGH-iCJD can be 
acquired from cell free systems, in addition to animal trans-
mission studies, as predicted for hDM-iCJD by Kobayashi 
et al. [20] and subsequently demonstrated by Takeuchi 
et al. [34].
The molecular mechanism of the trace-back phenom-
enon is not fully understood, but the data of Kitamoto and 
coworkers points to a key role for the intermediate PrPres 
type, termed type i. In this light, it is also tempting to sug-
gest that our data points to the sCJD MV2K subtype as the 
source of the UK hGH-iCJD epidemic. It is plausible that 
the combination of the 20 kDa type i and 19 kDa type 2 
PrPres conformational variants found in sCJD MV2K might 
engender enhanced genotypic host range according to the 
principles of the conformational selection model proposed 
by Collinge and Clarke [7]. In this scheme, the MV2K sub-
type would transmit efficiently to MV individuals result-
ing in hGH-iCJD with a recognisable MV2K phenotype 
involving kuru plaques. The presence of type 2 PrPres in the 
type i + 2 isoform would also facilitate efficient transmis-
sion to PRNP codon 129 VV individuals and result in the 
recognisable VV2 phenotype lacking kuru plaques. Finally, 
the coexistence of type i with type 2 PrPres within the type 
2d or 2 doublet isoform might render MV2K more compat-
ible with transmission to PRNP codon 129 MM individu-
als, but only with extended incubation periods and produc-
ing a phenotype with PrPres type i and kuru plaques or, 
if molecular adaptation is complete, type 1 PrPres and an 
MM1 phenotype.
Alternatively, a sCJD VV2 source of infection in 
the hGH-iCJD cohort would involve a molecular strain 
adaptation-based model (rather than a molecular strain Ta
bl
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selection-based model) in which the PRNP codon 129 
polymorphism of the host imposes a modified PrPSc con-
formation on the infectious agent. The in vitro PrPres type 
switching we observed when sCJD VV2 was amplified in 
a mismatched substrate (MM) is entirely consistent with 
this second VV2 source adaptation-based model. These 
scenarios are summarised in Fig. 7a and the epidemic 
is plotted according to estimated incubation periods in 
Fig. 7b. The most relevant published humanised transgenic 
mouse model transmission data do not help in resolving 
the VV2/MV2 question, because the VV2 sCJD and MV2 
sCJD cases used transmitted with indistinguishable char-
acteristics in these mice. However, it is noteworthy that the 
most efficient transmission with the shortest incubation 
period was with the V2 strain (both VV2 and MV2 sCJD) 
in PRNP codon 129 VV mice [3]. Distinguishing between 
Fig. 6  PrPres analysis of PMCA reactions seeded with cerebral cor-
tex from case of sCJD and iCJD. a hGH-iCJD, hDM-iCJD and 
sCJD brain homogenate (seeds) were diluted in humanised trans-
genic mouse brain homogenate (substrate) of the PRNP codon 129 
MM (red dots) or VV (blue dots). Amplification factor is shown as 
the relative increase (fold) in PrPres signal after a single round of 
PMCA as determined by densitometry of the Western blotting sig-
nal. PMCA reactions were normalized by seed PrPres amount. PMCA 
of serial dilution of the hGH-iCJD MM seeds were also performed 
(hGH-iCJD20: 1/50, 1/100, 1/200, 1/400 and hGH-iCJD21: 1/4, 1/8, 
1/16, 1/32). PMCA experiments seeded with hGH-iCJD, hDM-iCJD 
and sCJD samples were performed twice independently and repeated 
at least four times for the reactions seeded with the hGH-iCJD MM 
cases. b PrPres type of MM hGH-iCJD cases 20 and 21 assessed 
before and after PMCA. PMCA reactions employed matched (MM) 
and mismatched (VV) PRNP transgenic mouse brain substrates. 
Each sample was run between a type 1 (left lane) and type 2 (right 
lane) reference standards from sCJD MM1 and VV2 subtype cases, 
respectively (T1 and T2). Study identification numbers of the hGH-
iCJD MM cases are indicated. c PrPres analysis of sCJD VV2 PMCA 
products detected by Western blot. sCJD VV2 brain homogenate was 
diluted and amplified in matched (MM) and mismatched (VV) codon 
129 substrate by a single round of PMCA. Samples corresponding to 
unamplified (Frozen) and amplified (PMCA) aliquots are shown with 
reference standards as described above. A total of 25 biological repli-
cates of hGH-iCJD, hDM-iCJD and sCJD were analysed
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sCJD VV2 and MV2K as the source of UK hGH-iCJD 
may be more than a formal difficulty given our recent 
finding that the proportion of PrPres derived from the two 
PRNP M and V alleles can vary dramatically in sCJD, 
such that some heterozygous sCJD cases might in effect 
contain only PrPres derived from the 129 V or the 129 M 
alleles [22]. Irrespective of mechanisms, the chronological 
sequence of cases (as judged by date of death and by esti-
mated incubation period) involves a gradual change from 
predominantly PRNP codon 129 VV cases first, then MV 
cases during the peak and finally MM cases later and a 
corresponding change from predominantly PrPres type 2, 
to more complex type i + 2 and then the two cases with 
PrPres type i and type 1.
Fig. 6  continued
Table 2  Comparison of two hGH-iCJD (MM) cases with differing pathological and molecular features
hGH-iCJD21 hGH-iCJD20
PRNP codon 129 genotype MM MM
Neuropathology Diffuse PrP positivity (resembling MM1  
sCJD and hDM-iCJD)
PrP positive kuru plaques present 
(similar to MV2K sCJD)
RT-QuIC seeding activity Shorter lag time (closer to MM1 sCJD) Long lag time
PrPres Type 1 (~21 kDa) Type i (~20 kDa)
PMCA efficiency Poor Greater
PMCA substrate preference None VV > MM
PMCA product PrPres mobility Type 1 MM Substrate Results In Upshift
VV Substrate Results In Downshift
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Implications for person‑to‑person transmission
The RT-QuIC and PMCA comparisons performed here did 
not support the hypothesis that human-to-human transmis-
sion of CJD results in acquired replicative efficiency [36]. 
Indeed, the RT-QuIC assay showed reduced rather than 
enhanced seeding activity in hGH-iCJD compared to the 
matched subtypes of sCJD suggesting that hGH-iCJD is 
not markedly more of a public health concern than its pre-
sumed source, sCJD. However, CJD surveillance systems 
in countries where contaminated batches of growth hor-
mone were used should remain vigilant for further cases 
of hGH-iCJD. Some of these cases may be identifiable by 
the presence of kuru plaques and the presence of PrPres 
type i. However, others cases may appear closely similar 
to the most common form of sCJD (MM1), and the only 
Fig. 7  The UK hGH-iCJD 
epidemic and the study out-
comes. a A summary of the 
molecular genetic finding of the 
hGH-iCJD cohort studied here 
showing correlations between 
PRNP codon 129 genotype, 
PrPres type and pathology, the 
genetics of the exposed group 
and the suspected source of 
the hGH-iCJD infectivity. b 
Graphic representation of the 
numbers of hGH-iCJD subtypes 
(PRNP codon 129 genotype and 
PrPres type) plotted according to 
increasing estimated incubation 
period
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indication of an iatrogenic aetiology may be in their medi-
cal history. The overriding message from the UK experi-
ence with hGH-iCJD and perhaps human prion diseases, 
more generally, is that poorly assessed risks can continue 
to have ramifications for patients years to decades after the 
risk source is itself recognised and removed. This point is 
underscored by a further case of hGH-iCJD being identi-
fied during the writing of this report in 2016, some 30 years 
after treatment with pituitary-derived hGH was abandoned 
in the UK.
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